I like very much this drug Aviptadil..., it is
" Vasoactive Intestinal Polypeptide " -- VIP.

It is an antiviral and immunomodulator ...
It is preventhing synthesis of cytokins and chemokines in the lungs ( including rantes ) ,
inhibits pro inflammatory TNF-alpha , IL-6 , IL-12 ,
promotes anti inflammatory IL-10...

And blocks ACE2 receptors ...

In lungs are rare cells called Alveoral type 2 cells , which are critical for a transmission of oxygen in the body , and are at very HIGH level with ACE2...
So this is why in respiratory failure ,they trying now in inhaler..

70% of VIP in our body is bound to lungs...
But we know that COVID-19 is multi-system disease.
This is why I believe that their inhaler will be great with our Leronlimab..

I will like to see study...

--1/3 patients on Aviptadil inhaler ..
--1/3 patients on Leronlimab
--1/3 patients on Aviptadil inhaler with Leronlimabb
I will not even bother with Remdesivir...

And I have this very strong feeling that Aviptadil and Leronlimab will be a BIG winner..


All IMO..